Avenge Bio

Avenge Bio was founded by an experienced team of proven biotech executives to develop transformative therapeutics which can potentially eradicate intractable solid tumors. Avenge Bio is developing our proprietary, allogeneic LOCOcyteTM platform for precision delivery of cytokines and other highly potent immunomodulatory molecules for a controlled period of time. Through this approach we are able to generate robust, local and systemic anti-tumor immune responses, without the toxicities associated with traditional immunotherapies. The LOCOcyteTM platform was developed from extensive research and experience of Dr. Omid Veiseh at Rice University and supported by Longitude Capital, CAM Capital, Perceptive Xontogeny, Rock Springs, Pappas Capital, and other leading healthcare investors. Together we are using the strength and efficiency of our platform to create a broad pipeline of therapeutics that target a wide range of difficult to treat solid tumors.

Avenge Bio Receives FDA Fast Track Designation for AVB-001, a Novel Cell Therapy Leveraging the LOCOcyte™ Immunotherapy Platform

Avenge®️ (@avengeworldwide) • Instagram photos and videos

Avenge Bio Developing Cell Generated Immunotherapies to Eradicate Solid Tumors

Avenge Bio Developing Cell Generated Immunotherapies to Eradicate Solid Tumors

New pinhead-sized beads kill ovarian, colorectal cancers by producing interleukin-2: mouse study

How far would YOU go to avenge a friend? 😈 Details on this insane story at link in bio, link in Stories, or go here:…

Avenge Bio Developing Cell Generated Immunotherapies to Eradicate Solid Tumors

BioCentury - Asif Ali to join Protagonist as CFO

Branding Process, Monderer Design

Organic Weed Killer Concentrate

Avenge Bio Developing Cell Generated Immunotherapies to Eradicate Solid Tumors

avengebio (@AvengeBio) / X

Avenge Bio Developing Cell Generated Immunotherapies to Eradicate Solid Tumors

Michael Heffernan on LinkedIn: I am excited to announce the closing of Avenge Bio's $45 million Series A…